PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 28, 2026Infectious Diseases and Therapy0 citationsOpen Access

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

BYBenjamin YarnoffMBMatthieu BeuveletSSSamira Soudani

Key Points

  • To evaluate the cost-effectiveness of nirsevimab compared to clesrovimab in preventing RSV-related diseases in infants in the U.S.
  • Modeling study design to compare nirsevimab and clesrovimab
  • Sensitivity analyses to test robustness of findings
  • Assessment of healthcare utilization and costs
  • Nirsevimab is more cost-effective than clesrovimab
  • Nirsevimab offers greater clinical protection against RSV
  • Lower healthcare resource utilization associated with nirsevimab compared to clesrovimab

Abstract

Our findings predict that nirsevimab is economically dominant over clesrovimab while providing greater clinical protection against RSV-related disease in these scenarios. These results are robust to sensitivity analyses with nirsevimab consistently estimated as reducing healthcare resource utilization and total costs compared to clesrovimab across assumptions related to clesrovimab duration of cumulative efficacy as well as variation in key model parameters.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yarnoff et al. (2026) studied this question.

synapsesocial.com/papers/69a287130a974eb0d3c02863https://doi.org/10.1007/s40121-026-01311-w
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States2026 · 1 citations
  2. 2Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants2026
  3. 3P-650. Cost-Effectiveness Analysis of Clesrovimab for Protection against Infant Respiratory Syncytial Virus Disease in the United States2026
  4. 4Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong2025 · 1 citations
  5. 5Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants2025